Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

about

Serum fatty acid profile in psoriasis and its comorbidity.

P2860

Q33840850-9826489D-9EF7-4B6E-B949-1B6D830A2AF9

P2860

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

Item

http://www.wikidata.org/entity/Q37575141

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@en

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@nl

type

Item

label

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@en

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@nl

prefLabel

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@en

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@nl

P1476

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

@en

P2093

A Baran

http://www.w3.org/2001/XMLSchema#string

H Myśliwiec

http://www.w3.org/2001/XMLSchema#string

I Flisiak

http://www.w3.org/2001/XMLSchema#string

Joanna Bacharewicz-Szczerbicka

http://www.w3.org/2001/XMLSchema#string

M Świderska

http://www.w3.org/2001/XMLSchema#string

P2860

Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study

The human fatty acid-binding protein family: evolutionary divergences and functions

Fatty acid transporters in skin development, function and disease

Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.

Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study.

Heart-type fatty acid-binding protein is essential for efficient brown adipose tissue fatty acid oxidation and cold tolerance.

A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.

Psoriasis and metabolic syndrome.

Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.

P2888

s11745-016-4211-4

P304

51-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11745-016-4211-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joanna Bacharewicz-Szczerbicka

P577

2016-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27864793

http://www.w3.org/2001/XMLSchema#string

P921

fatty acid

P932

5222907

http://www.w3.org/2001/XMLSchema#string

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

about

P2860

P2860

Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932